Nutriband Strengthens Patent Protection for Abuse-Deterrent Transdermal Tech

  • Nutriband filed a non-provisional patent application on October 8, 2026, to strengthen its AVERSA™ abuse-deterrent transdermal technology.
  • The new patent application covers improved aversive formulations and coating application methods to enhance abuse deterrence.
  • If granted, the patent could extend worldwide protection for AVERSA™-based products like AVERSA™ FENTANYL until 2046.
  • AVERSA™ technology is already protected by patents in 46 countries, including the U.S., Europe, Japan, and China.

Nutriband's move to strengthen its patent portfolio reflects the strategic importance of intellectual property in the pharmaceutical industry, particularly for abuse-deterrent technologies. The filing comes amid growing regulatory scrutiny and market demand for safer opioid delivery systems. The company's ability to secure and leverage this patent could significantly impact its competitive positioning and long-term revenue potential.

Patent Approval
Whether the USPTO will grant the new patent application, which could extend protection for AVERSA™-based products until 2046.
Regulatory Hurdles
The pace at which Nutriband can secure FDA approval for its abuse-deterrent fentanyl patch and other products.
Market Adoption
How effectively Nutriband can commercialize its AVERSA™ technology in a competitive pharmaceutical landscape.